EGFR and non-small cell lung carcinoma: The novelty of these findings is that they have identified MUC1-C as an unanticipated effector of a NSCLC STAT1-mediated inflammatory memory pathway that drives resistance to treatment with (i) combinations of osimertinib+MET TKIs, and (ii) a 4th generation TKI targeting NSCLC cells with the EGFR(T790M/C797S) compound mutation.